Drawing for PASYLATION

USPTO serial 79126686

PASYLATION

Reviewed by CopyMark Law Group

Reg. 4483086Status 706Registered
Filing date
Status date
Registration date
Feb 18, 2014
Examiner
BEVERLY, JOSETTE MICHELLE
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with PASYLATION?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Anthony G. Craig

Anthony G. Craig Sci-Law Strategies, PCP.O. Box 1729SOLANA BEACH, CA 92075United States

Goods and services

ClassDescriptionStatusFirst use
001[ Chemicals and biochemicals for research and laboratory purposes excluding for medical or veterinary purposes, and for industrial and scientific purposes; [ unprocessed artificial resins, unprocessed plastics; ] chemical and biological preparations for medical research and medical and scientific purposes ]SECTION 71 - CANCELLED—
005[ Pharmaceutical and veterinary preparations and preparations for human medical purposes for use in treating growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; [ sanitary preparations for medical purposes; dietetic substances adapted for medical use, namely, nutritional supplements containing proteins, peptides, food for babies; preparations for destroying vermin; fungicides, herbicides; ] pharmaceutical and diagnostic preparations for medical [, dental and forensic ] purposes and for purposes of [ forensic medicine and ] laboratory medicine, namely, pharmaceutical and diagnostic preparations for diagnosis, prevention, treatment or cure of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; testing reagents in kit form for medical, [ dental and forensic ] purposes and for purposes of [ forensic medicine and ] laboratory medicine, namely, medical [ and forensic ] diagnostic reagents and assays for testing of body tissues and body fluids; chemical and biotechnological preparations for medical and diagnostic purposes, namely, reagents and solvents for sample preparation, modification and manipulation of cells and for performing of marking, separation, isolation, purification, amplification and/or analytical methods for biopolymers, in particular nucleic acids, proteins, macromolecules and biologically active substances for diagnostic purposes included in this class; medicaments for preventive, curative and palliative purposes for preventing, treating or curing of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; medical biomarkers, in particular for preventative, diagnostic, prognostic or predictive purposes, namely, polypeptide sequences; [ medical preparations, namely, kits for laboratory medicine in particular for preventive, diagnostic, prognostic or predictive purposes, namely, diagnostic kits consisting primarily of proteins, buffers, and reagents for use in detecting growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; ] biomolecules for medical purposes, namely, proteins, peptides and small molecule drugs with conjugated polypeptide sequences for binding of active substances; medical preparations for analytical purposes, namely, reagents for detecting growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases; preparations for health care, namely, for diagnosis, prevention, treatment, or cure of growth deficiencies, inflammation, infections, obesity, diabetes, malignancies, metabolic diseases, cancer, cardiovascular diseases, diseases of the CNS, eye diseases, bone diseases ]SECTION 71 - CANCELLED—
042Scientific and technological services and research, namely, scientific research, analysis, testing, in the fields of chemistry, genetics, biology, biotechnology and biochemistry; [ technical services, namely, computer diagnostic services in the field of DNA, RNA and protein expression, detection and analysis and respective design services, in particular in the fields of chemistry, genetics, biology, biotechnology and biochemistry; industrial analysis and research services in the field of medical, dental, forensic and scientific research; design and development of computer hardware and software; ] services of a chemical and biochemical laboratory; scientific research including conducting of scientific examinations; and preparation of scientific opinions; quality checking, namely, quality evaluation services for the medical and pharmaceutical industry; [ design and development of programs for data processing; ] consultancy for scientific, laboratory and research purposes in the field of chemistry, genetics, biology, biotechnology and biochemistry; [ scientific services of a technical measuring and test laboratory; ] technological consulting services pertaining to scientific and industrial scientific research in the fields of generation, technical processing and technical analysis of biomaterials and medically relevant dataACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 30, 2025INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Jun 8, 2025INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Oct 7, 2024NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Oct 7, 202471AGREGISTERED-SEC.71 ACCEPTED—
Oct 7, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Feb 12, 2024ES71TEAS SECTION 71 RECEIVED—
Feb 18, 2023REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Nov 4, 2022RNWLINTERNATIONAL REGISTRATION RENEWED—
Jul 2, 2022NREPNEW REPRESENTATIVE AT IB RECEIVED—
Sep 9, 2021INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Aug 29, 2021INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Feb 13, 2021INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Jan 1, 2021INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Dec 31, 2020INPCINVALIDATION PROCESSED—
Dec 29, 2020NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Dec 29, 2020C75PREGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.—
Dec 27, 2020INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Oct 2, 2020EROPTEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED—
May 12, 2020PR75POST REGISTRATION ACTION MAILED - SEC. 71 & 15—
Apr 6, 2020APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Feb 18, 2020ES75TEAS SECTION 71 & 15 RECEIVED—
Feb 18, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 18, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Feb 18, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 18, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 18, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Feb 18, 2019REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jul 13, 2017NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jun 27, 2014FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jun 6, 2014FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jun 6, 2014FIMPFINAL DISPOSITION PROCESSED—
May 18, 2014FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Feb 18, 2014R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 3, 2013NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 3, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 2, 2013GPNXNOTIFICATION PROCESSED BY IB—
Nov 13, 2013OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Nov 13, 2013OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Nov 13, 2013NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 30, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Oct 29, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 26, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 26, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 20, 2013ALIEASSIGNED TO LIE—
Sep 19, 2013ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 19, 2013REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 19, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 23, 2013RFNTREFUSAL PROCESSED BY IB—
Mar 28, 2013RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 28, 2013RFRRREFUSAL PROCESSED BY MPU—
Mar 28, 2013RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 27, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 22, 2013MAFRAPPLICATION FILING RECEIPT MAILED—
Mar 18, 2013DOCKASSIGNED TO EXAMINER—
Mar 18, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 15, 2013REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance